Studies
Rofecoxib improves quality of life in patients with hip or knee osteoarthritis
Robert Theiler, Heike A. Bischoff, Meinrad Good, Daniel Uebelhart
Swiss Medical Weekly SMW (2002) 132, 566-573.
PDF Version of this Article PDF, 129.99 KB
A major goal of osteoarthritis (OA) treatment is pain management to improve function and maximize quality of life. Rofecoxib is a highly selective inhibitor of cyclooxygenase-2 used for the symptomatic treatment of inflammation and pain in patients with osteoarthritis of the hip or the knee. The primary aim of this study was to assess the effects of rofecoxib on quality of life in elderly patients with painful OA of the hip or knee, who were not responsive to or had adverse events from previous NSAID-therapy. In addition the switch pattern of NSAIDs in these patients was recorded.
Experience with Rosiglitazon in Patients wit Diabetes Type 2 (A Phase III B Study)
German Paper
Eric Bandle, Urs Kientsch, Meinrad Good
Ars Medici (2001) 25/26, 1219-1222
PDF Version of this Article PDF, 55.95 KB
In dieser bei 28 Diabetologen in der Schweiz durchgeführten Phase-IIIB-Studie wurden 184 Typ-2-Diabetes-Patienten eingeschlossen, wovon 114 Patienten die Studie gemäss Studienprotokoll beendeten. Die unter Diätvorschrift stehenden Patienten wurden mit dem oralen Antidiabetikum Rosiglitazon während 26 Wochen behandelt, entweder als Monotherapie oder in Kombination mit den bisherigen oralen Antidiabetika (91% der Patienten). Die Konzentration der Nüchternplasmaglukose (NPG), der primäre Endpunkt dieser Studie, erniedrigte sich unter der Behandlung mit Rosiglitazon (n=114) signifikant um 2,1 mmol/l.
An Open Multi-Centre Swiss Study on Dose-Dependent Efficacy, Safety and Tolerability of Oral Sumatriptan in The Treatment of Migraine Under Practice Conditions
Gerhard Jenzer, Barbara Henggeler, Meinrad Good, Beat Althaus
Schweiz Arch Neurol Psych (2000) 151 (2), 1- 5.
(No PDF available)
Objectives of this open study were to determine the efficacy, safety and tolerability of the 50 mg and 100 mg oral doses of sumatriptan in migraine patients on an out-patient basis. All patients had to treat the first two attacks with 50 mg. The second treatment with the 100 mg dose of further two attacks was performed solely with those patients who were not content with the treatment of the 50 mg dose.
